AstraZeneca (LON:AZN) Given “Outperform” Rating at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of AstraZeneca (LON:AZN) in a report released on Tuesday,Digital Look reports. The firm currently has a £145 price target on the biopharmaceutical company’s stock.

AZN has been the subject of several other reports. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research report on Wednesday, September 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Wednesday. Citigroup upped their price objective on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Finally, Berenberg Bank reiterated a “buy” rating and set a £160 price objective on shares of AstraZeneca in a research report on Thursday, September 3rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of £151.14.

AstraZeneca Price Performance

AZN stock opened at £118.18 on Tuesday. The firm has a 50 day simple moving average of £124.79 and a two-hundred day simple moving average of £136.10. The stock has a market cap of £183.28 billion, a PE ratio of 17.69, a P/E/G ratio of 0.86 and a beta of 0.20. AstraZeneca has a one year low of £107.84 and a one year high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.